Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 8 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

BENZODIAZEPINES AS SOLE TREATMENT vs placebo

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
RR 0.89 [0.57, 1.38]
8 studies · 440 participants
Very low

BENZODIAZEPINES AS SOLE TREATMENT vs placebo

Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 161 participants
Very low

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
RR 1.36 [0.81, 2.3]
19 studies · 1185 participants
Very low

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia

It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to adverse effects (overall tolerability… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
RR 3.24 [0.68, 15.45]
6 studies · 415 participants
Very low

Benzodiazepines vs phenobarbital (as active placebo)

Acceptability · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Benzodiazepines vs placebo

Acceptability · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 2.73 [0.15, 48.04]
3 studies · 56 participants
Very low

Benzodiazepines vs antipsychotics

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
RR 0.73 [0.45, 1.18]
13 studies · 738 participants
Very low

Benzodiazepines vs antipsychotics

Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia

It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to adverse effects (overall tolerability… compared with ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
RR 13 [0.78, 216.39]
5 studies · 444 participants
Very low